King Faisal Specialist Hospital & Research Center — CureCurrent

How to interpret these research links

Connected source records

The exact organization name King Faisal Specialist Hospital & Research Center appears in 21 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials21

Recruiting shown2

Roles2

SourceClinicalTrials.gov

Clinical trials

21 shown

Use of Magtrace Bracketing for Excision of Lesion and Sentinel Lymph Node Localization in Breast Conserving Surgery for Breast CancerNCT07844473 · lead sponsor · 2026-07-24

This Study Aims to Compare Asthma Control in Children Monitored With FeNO Against a Historical Cohort Without FeNO. Secondary Objectives Include Evaluating Associations Between FeNO Levels, ACT/C-ACT Scores, Eosinophil Counts, FEV1%, ICS Adherence, and Exacerbation Frequency.NCT07788534 · lead sponsor · 2025-11-12

The Impact of Type 2 Diabetes Mellitus on Cardiovascular Events in Saudi Arabia Now and FutureNCT06674161 · lead sponsor · 2024-11-30

NOT_YET_RECRUITING

Degludec Insulin Use in Critically Ill PatientsNCT06056167 · lead sponsor · 2023-05-17

Somatostatin in Living Donor Liver TransplantationNCT04107428 · lead sponsor · 2019-12-01

Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer PatientsNCT02628132 · lead sponsor · 2016-11-01

Optic Nerve Sheath Diameter as a Screening Test for Increased Intracranial PressureNCT02338284 · lead sponsor · 2014-10-01

Does Vitamin D Improve Glycemic Control in Type II DM?NCT01170442 · lead sponsor · 2011-12-01

Does Vitamin D Reduce Risk of Developing Type II DM in High Risk IndividualsNCT01170468 · lead sponsor · 2011-12-01

Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast CancerNCT01530607 · lead sponsor · 2009-11-01

Phase III Trial of High Dose vs. Standard Dose Vit D2 With Docetaxel in Met Breast caNCT00944424 · lead sponsor · 2009-07-01

The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast CancerNCT01311037 · lead sponsor · 2009-01-01

Pre-operative Chemotherapy in Operable Breast Cancer, Phase III Study Comparing a Short Intensive Pre-operative Chemotherapy With the Same Therapy Initiated Shortly After Surgery(Peri-operatively)(POCOB)EORTC 10902)NCT00544505 · lead sponsor · 2007-09-01

Post Operative Adjuvant Chemotherapy Followed by Adjuvant Tamoxifen vs Nil for Patients With Operable Breast CancerNCT00538330 · lead sponsor · 2007-09-01

Intensive Sequential Chemotherapy With Adriamycin Taxol and Cytoxan in the Treatment of Locally Advanced Breast CancerNCT00538395 · lead sponsor · 2007-09-01

Phase II Study of Neoadjuvant Chemotherapy With Doxorubicin Followed by Docetaxel-Cisplatin in Locally Advanced Breast CancerNCT00538525 · lead sponsor · 2007-09-01

Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast CancerNCT00535509 · lead sponsor · 2007-06-01

Prospective & Retrospective Data Collection of Breast Cancer Cases From 2000 to PresentNCT00534755 · lead sponsor · 2005-06-01

Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Clinical Early Stages of Non-small Cell Lung CancerNCT00540280 · lead sponsor · 2003-10-01

Non-Invasive MASLD Diagnosis & T2D Remission BiomarkersNCT07172997 · collaborator · 2025-01-01

ACTIVE_NOT_RECRUITING

Echocardiographic Assessment and CLInical imPlication of Functional tricuSpid rEgurgitation in Heart Failure With Reduced or Preserved Ejection FractionNCT05209919 · collaborator · 2021-11-11

Drugs studied in this sponsor's trials

6 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing King Faisal Specialist Hospital & Research Center as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

placebo3

durvalumab1

insulin degludec1

paclitaxel1

somatostatin1

tamoxifen1

placebo RxCUI 8375 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials durvalumab RxCUI 1919503 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial insulin degludec RxCUI 1670007 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial paclitaxel RxCUI 56946 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial somatostatin RxCUI 9939 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial tamoxifen RxCUI 10324 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor19

collaborator2

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.